The Role of the Signal-to-Cutoff Ratio in Automated Anti-HCV Chemiluminescent Immunoassays by Referring to the Nucleic Acid Amplification Test and the Recombinant Immunoblot Assay
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Following discontinuation of the recombinant immunoblot assay (RIBA), the only available supplementary test for the detection of hepatitis C virus (HCV) is the nucleic acid amplification test (NAAT). However, the NAAT does not adequately detect past HCV. Consequently, it is hard to distinguish between past HCV infection and biological false positivity with an anti-HCV result alone. We assessed the diagnostic performance of two immunoassays: the ARCHITECT anti-HCV chemiluminescent microparticle immunoassay (CMIA; Abbott Diagnostics, Wiesbaden, Germany) and the Access HCV Ab PLUS chemiluminescent immunoassay (CIA; Bio-Rad, Marnes-la-Coquette, France). We also explored an optimized algorithm to determine the anti-HCV results. Methods: We tested 126,919 patients and 44,556 individuals who underwent a medical checkup. RIBA and NAAT were conducted for samples that tested anti-HCV-positive using CMIA and CIA. We assessed the optimal signal-to-cutoff (S/CO) ratio in HCV-positive samples. Results: In total, 1,035 blood samples tested anti-HCV-positive. Of these, RIBA was positive in 512, indeterminate in 160, and negative in 363 samples. One hundred sixty-five samples were NAAT-positive. Diagnostic sensitivity and positive predictive value (PPV) were 96.7% and 52.1%, respectively, for CMIA, and 94.7% and 72.3%, respectively, for CIA. The optimal S/CO ratio was 5.2 for CMIA and 2.6 for CIA at 95% PPV. In total, 286 samples tested positive in CMIA and 444 in CIA, while 443 samples tested positive in both assays. Conclusions: It is hard to determine anti-HCV positivity based on the S/CO ratio alone. However, this study elucidated the role of the S/CO ratio by using the NAAT and RIBA.
Abstract
Background: Following discontinuation of the recombinant immunoblot assay (RIBA), the only available supplementary test for the detection of hepatitis C virus (HCV) is the nucleic acid amplification test (NAAT). However, the NAAT does not adequately detect past HCV. Consequently, it is hard to distinguish between past HCV infection and biological false positivity with an anti-HCV result alone. We assessed the diagnostic performance of two immunoassays: the ARCHITECT anti-HCV chemiluminescent microparticle immunoassay (CMIA; Abbott Diagnostics, Wiesbaden, Germany) and the Access HCV Ab PLUS chemiluminescent immunoassay (CIA; Bio-Rad, Marnes-la-Coquette, France). We also explored an optimized algorithm to determine the anti-HCV results. Methods: We tested 126,919 patients and 44,556 individuals who underwent a medical checkup. RIBA and NAAT were conducted for samples that tested anti-HCV-positive using CMIA and CIA. We assessed the optimal signal-to-cutoff (S/CO) ratio in HCV-positive samples. Results: In total, 1,035 blood samples tested anti-HCV-positive. Of these, RIBA was positive in 512, indeterminate in 160, and negative in 363 samples. One hundred sixty-five samples were NAAT-positive. Diagnostic sensitivity and positive predictive value (PPV) were 96.7% and 52.1%, respectively, for CMIA, and 94.7% and 72.3%, respectively, for CIA. The optimal S/CO ratio was 5.2 for CMIA and 2.6 for CIA at 95% PPV. In total, 286 samples tested positive in CMIA and 444 in CIA, while 443 samples tested positive in both assays. Conclusions: It is hard to determine anti-HCV positivity based on the S/CO ratio alone. However, this study elucidated the role of the S/CO ratio by using the NAAT and RIBA.
참고문헌 (26)
- Aldamiz-Echevarria L, "Asymmetric dimethylarginine, endothelial dysfunction and renal disease", Int J Mol Sci, 13, pp.11288~11311 (2012)[DOI]
- Liu X, "Effect of asymmetric dimethlarginine (ADMA) on heart failure development", Nitric Oxide, 54, pp.73~81 (2016)[DOI]
- Tain YL, "Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA)", Toxins (Basel), 9, pp.E92~ (2017)[DOI]
- McCarty MF, "Asymmetric dimethylarginine is a well-established mediating risk factor for cardiovascular morbidity and mortality-should patients with elevated levels be supplemented with citrulline?", Healthcare (Basel), 4, pp.E40~ (2016)[DOI]
- Erbil MK, "Metabolism of asymmetric dimethylarginine and its clinical significance", Turk J Bioch, 37, pp.99~105 (2012)[DOI]
- El Dayem SM, "Asymmetric dimethyl L-arginine, nitric oxide and cardiovacular disease in adolescent type 1 diabetics", J Pediatr Endocrinol Metab, 27, pp.437~444 (2014)
- Taskiran B, "Effect of exercise on ADMA level in type 2 diabetes mellitus", Balkan Med J, 29, pp.62~67 (2012)[DOI]
- Sitar ME, "Asymmetric dimethylarginine and its relation as a biomarker in nephrologic diseases", Biomark Insights, 11, pp.131~137 (2016)
- Ittermann T, "L-Arginine derivatives are associated with the hyperthyroid state in the general population", Thyroid, 26, pp.212~218 (2016)[DOI]
- Aydemir O, "Asymmetric dimethylarginine and L-arginine levels in neonatal sepsis and septic shock", J Matern Fetal Neonatal Med, 28, pp.977~982 (2015)[DOI]
- Ferrigno A, "Liver plays a central role in asymmetric dimethylarginine-mediated organ injury", World J Gastroenterol, 21, pp.5131~5137 (2015)[DOI]
- Mengeloglu Z, "High asymmetric dimethylarginine (ADMA) levels in patients with brucellosis", Inflammation, 37, pp.127~131 (2014)[DOI]
- Baranyi A, "Asymmetric dimethylarginine responses during interferon-<TEX>$\alpha$<", TEX>- induced depression in patients with chronic hepatitis C infection, 2014, pp.76, 197~207
- Hu J, "Complete and incomplete hepatitis B virus particles: formation, function, and application", Viruses, 9, pp.56~ (2017)[DOI]
- Sandhu P, "Hepatitis B virus immunopathology, model systems, and current therapies", Front Immunol, 8, pp.436~ (2017)
- An J, "Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial", BMC Gastroenterol, 17, pp.15~ (2017)[DOI]
- Joshi U, "Hepatitis B virus induced cytoplasmic antineutrophil cytoplasmic antibody-mediated vasculitis causing subarachnoid hemorrhage acute transverse myelitis, and nephropathy: a case report", J Med Case Rep, 11, pp.91~ (2017)[DOI]
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)[DOI]
- Lluch P, "Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis", World J Gastroenterol, 21, pp.9466~9475 (2015)[DOI]
- Nickovic V, "Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis", Vojnosanit Pregl, 69, pp.686~691 (2012)[DOI]
- Brenner T, "L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure", Mediators Inflamm, 2012, pp.210454~ (2012)
- Mookerjee RP, "Increasing dimethylarginine levels are associated with adverse clinical outcome in several alcoholic hepatitis", Hepatology, 45, pp.62~71 (2007)[DOI]
- Beltran LM, "Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection", PLoS One, 9, pp.e90541~ (2014)[DOI]
- Kuller LH, "Inflammatory and coagulation biomarkers and mortality in patients with HIV infection", PLoS Med, 5, pp.e203~ (2008)[DOI]
- Kristoffersen US, "Reduction in circulating markers of endothelial dsyfunction in HIV-infected patients during antiretroviral therapy", HIV Med, 10, pp.79~87 (2009)[DOI]
- Lluch P, "Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C", Scand J Gastroenterol, 44, pp.224~228 (2009)[DOI]